不同给药途径应用重组人红细胞生成素治疗血透患者肾性贫血的疗效与安全性

The clinical effect and safety of different administration ways of rhEPO in treatment of hemodialysis-induced renal anemia

目的:观察不同给药途径应用重组人红细胞生成素(rhEPO)对维持性血透(MHD)患者贫血的疗效及安全性,为临床选择rhEPO的最佳给药途径提供依据。方法:选取86例MHD患者随机分为静脉注射(43例)和皮下注射(43例)两组,分别在治疗前、治疗后1,2,3个月空腹抽血检测血红蛋白(Hb)、红细胞压积(Hct)、红细胞计数(RBC),并观察副作用及护理并发症。结果:两组治疗后Hb、Hct、RBC均较前明显上升(P<0.05),两组间比较无统计学意义,但皮下组较静脉组易发生护理并发症。结论rhEPO治疗肾性贫血两种给药途径均能有效改善患者的贫血情况,但静脉注射更为安全。

Objective：To observe the clinical effect and safety of two different administration ways of recombinant human erythropoietin （rhEPO） in treatment of hem odialysis-induced renal anemia, so as to identify a preferable way. Methods： 86 patients undergoing maintenance hemodialysis （MHD） were randomly divided into two groups, the intravenous group of 43 cases and the subcutaneous 43 cases. Blood sample was taken before, and 1,2,3 months after the administration of rhEPO in each case, hemoglobin （Hb）,hematocrit （HCT） and red blood cell count（RBC） were tested, the side effects and complications were also recoded. Results： All of the three anemic testing items after the treatment of rhEPO were significantly higher than before in both groups, but no statistical difference was demonstrated between the two groups. Subcutaneous way had a higher possibility to cause nursing complications, Conclusions： The treatment of rhEPO ameliorated hemodial ysis-induced renal anemia either in intravenous way or in subcutaneous way, but intravenous administration was safer.